UroGen Pharma (URGN) Current Assets (2016 - 2026)

UroGen Pharma (URGN) has 11 years of Current Assets data on file, last reported at $237.5 million in Q1 2026.

• Quarterly Current Assets changed 0.12% year-over-year to $237.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $237.5 million (changed 0.12% YoY) and the FY2025 annual result came in at $186.0 million, down 32.63% from the prior year.
• Current Assets improved to $237.5 million in Q1 2026, from $186.0 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $295.1 million in Q3 2024 to a low of $81.3 million in Q2 2023.
• A 5-year average of $185.4 million and a median of $182.1 million in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2024 — Current Assets surged 242.99% — and 2025, when it slumped 42.88%.
• Tracing URGN's Current Assets over 5 years: stood at $128.9 million in 2022, then soared by 31.25% to $169.2 million in 2023, then jumped by 63.21% to $276.1 million in 2024, then sank by 32.63% to $186.0 million in 2025, then rose by 27.65% to $237.5 million in 2026.
• The last three Current Assets figures came in at $237.5 million (Q1 2026), $186.0 million (Q4 2025), and $168.5 million (Q3 2025), per Business Quant data.